Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
Koos P J van DamAdriaan G VolkersLuuk WieskeEileen W StalmanLaura Y L KummerZoé L E van KempenJoep KillesteinSander W TasLaura BoekelGerrit J WolbinkAnneke J van der KooiJoost RaaphorstR Bart TakkenbergGeert R A M D'HaensPhyllis I SpulsMarcel W BekkenkAnnelie H MustersNicoline F PostAngela L BosmaMarc L HilhorstYosta VegtingFrederike J BemelmanAlexandre E VoskuylBo BroensAgner Parra SanchezCécile A C M van ElsJelle de WitAbraham RutgersKarina de LeeuwBarbara HorváthJan J G M VerschuurenAnnabel M RuiterLotte van OuwerkerkDiane van der WoudeRenée C F AllaartY K Onno TengPieter van PaassenMatthias H BuschPapay B P JallahEsther BrussePieter A van DoornAdája E BaarsDirk Jan HijnenCorine R G SchreursW Ludo van der PolH Stephan GoedeeMaurice SteenhuisSofie KeijzerJim B D KeijserOlvi CristianawatiAnja Ten BrinkeNiels J M VerstegenS Marieke van HamTheo RispensTaco W KuijpersMark LöwenbergKoos P J van Damnull nullPublished in: BMC infectious diseases (2023)
NL74974.018.20, Trial ID: NL8900. Registered on 9 September 2020.
Keyphrases
- disease activity
- immune response
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- study protocol
- phase iii
- phase ii
- dendritic cells
- oxidative stress
- clinical trial
- toll like receptor
- respiratory syndrome coronavirus
- coronavirus disease